



**FOLEY & LARDNER LLP
ATTORNEYS AT LAW**

WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 600
WASHINGTON, D.C. 20007-5143
202.672.5300 TEL
202.672.5399 FAX
www.foley.com
WRITER'S DIRECT LINE
202.295.4039
nbeaver@foley.com EMAIL

January 29, 2020

VIA REGULATIONS.GOV

Division of Dockets Management (HFA-305)
Food and Drug Administration
Department of Health and Human Services
5360 Fishers Lane, Room 1061
Rockville, MD 20852

RE: Withdrawal of Citizen Petition; Docket No. FDA 2020-P-0436

Dear Sir or Madam:

Petitioner requests withdrawal of the above-referenced citizen petition requesting that the Commissioner of Food and Drugs not approve any abbreviated new drug application ("ANDA") for any generic version or other pharmaceutical alternative of ALINIA® (nitazoxanide) tablets ("Alinia® Tablets"), for oral use and ALINIA® (nitazoxanide) for oral suspension ("Alinia® Oral Suspension") (collectively "Alinia®") unless and until the applicant satisfies all of the conditions set forth in this petition. Consequently, a formal response to Docket No. FDA-2020-P-0436 is no longer necessary.

Sincerely yours,

A handwritten signature in blue ink, appearing to read "Nathan A. Beaver", followed by a horizontal line.

Nathan A. Beaver
Regulatory Counsel to
Romark Laboratories, L.C.

AUSTIN
BOSTON
CHICAGO
DALLAS
DENVER

DETROIT
HOUSTON
JACKSONVILLE
LOS ANGELES
MADISON

MEXICO CITY
MIAMI
MILWAUKEE
NEW YORK
ORLANDO

SACRAMENTO
SAN DIEGO
SAN FRANCISCO
SILICON VALLEY
TALLAHASSEE

TAMPA
WASHINGTON, D.C.
BRUSSELS
TOKYO